Is It Time To Review Stock News? SCYNEXIS (NASDAQ:SCYX)

SCYNEXIS (NASDAQ:SCYX) spotted trading -41.58% off 52-week high price. On the other end, the stock has been noted 217.14% away from the low price over the last 52-weeks. The stock changed 3.74% to recent value of $1.11. The stock transacted 174681 shares during most recent day however it has an average volume of 332.55K shares. The company has 53.15M of outstanding shares and 52.76M shares were floated in the market.

On Aug. 7, 2019, SCYNEXIS (NASDAQ:SCYX) a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, revealed financial results for the quarter ended June 30, 2019, and provided an update on recent clinical developments.

We are pleased with the rapid enrollment observed in our Phase 3 VANISH program for vulvovaginal candidiasis (VVC), which underscores the significant unmet need in this patient population, said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. We look forward to sharing top-line data from the U.S. study in the first quarter of 2020, and from the global study in the second quarter of 2020. We are making great progress toward our goal of a planned New Drug Application (NDA) submission for VVC in the second half of 2020.

Dr. Taglietti continued, We are committed to maximizing the full value of ibrexafungerp in multiple settings. As we approach important milestones for our VVC registration program, we are also excited by the promising data supporting the potential role of oral ibrexafungerp as a treatment for a broad range of life-threatening, hospital-based, fungal infections, including Candida auris and other multidrug-resistant pathogens for which few existing treatment options are available.

Ibrexafungerp (formerly SCY-078), the first representative of a novel family of antifungal compounds referred to as triterpenoids, is being developed for oral and intravenous (IV) administration and is in clinical development for the treatment of both serious outpatient fungal infections, including VVC, and hospital-based life-threatening fungal infections, including invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. If approved, ibrexafungerp could potentially address significant unmet medical needs as the only oral non-azole antifungal therapy.

Its earnings per share (EPS) expected to touch remained 69.70% for this year.

According to the most recent quarter its current ratio was 8.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of -6.66% from the mean of 20 days, -8.86% from mean of 50 days SMA and performed -3.32% from mean of 200 days price. Company’s performance for the week was -0.89%, -13.28% for month and YTD performance remained 130.43%.

Leave a Reply

Your email address will not be published. Required fields are marked *